TXG
10x Genomics, Inc. [TXG] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TXG Stock Summary
Top TXG Correlated Resources
TXG
Top 10 Correlated ETFs
TXG
Top 10 Correlated Stocks
TXG
In the News
10x Genomics: Recent Performance Amplifies My Bullish Conviction
10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance in both single-cell and spatial biology portfolios. Despite challenges in the Chinese market and a decrease in gross margin, 10x Genomics remains well-positioned for growth with a strong cash position.
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.57 per share a year ago.
Goldman Sachs Maintains 10x Genomics Inc – (TXG) Sell Recommendation
Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation.
10x Genomics: Growth Outweighing The Risks
10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics is becoming an entrenched name. After performing some analysis, I believe the company's growth record and prospects outweigh the risks at this point. I am moving it up on my watch list. The medicines of the future will rely upon the technology that 10x is involved in. Clearly, this could lead to a massive market opportunity for the company.
Red-Hot Quality Opportunities in Genomics
The health care sector is currently undergoing a remarkable transformation. The recent focus on genomics has empowered medical professionals to diagnose patients more objectively and adopt proactive measures to maintain the well-being of larger populations.
CEO Serge Saxonov Sells 2,602 Shares of 10x Genomics Inc (TXG)
On May 23, 2023, Serge Saxonov, CEO of 10x Genomics Inc ( TXG , Financial), sold 2,602 shares of the company's stock. This insider sell comes amidst a year of insider transactions that have seen Saxonov sell a total of 15,934 shares and make no purchases.
How 10x Genomics Provides A View Into The Body's Cellular Warfare
It could be an inflection year for 10x Genomics, one analyst says. TXG stock bounded off a low in October and is now on a seven-month sprint.
3 DNA Stocks to Buy for the Synthetic Biology Revolution
Biology is the study of life. And synthetic biology is the creation of new life for new purposes.
A Deep Dive Into 10x Genomics, A Promising Portfolio
10x Genomics develops cutting-edge platforms for single-cell and spatial analysis, driving advances in disease research and drug discovery. Despite market fluctuations, their strong product pipeline is expected to fuel revenue growth and expand their customer base.
TXG Financial details
TXG Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.77 | 6.29 | 2.95 | 4.44 | 4.54 | |
| Net income per share | -1.36 | -0.8 | -5.37 | -0.53 | -1.46 | |
| Operating cash flow per share | -0.92 | 0.89 | -2.15 | -0.19 | -0.3 | |
| Free cash flow per share | -1 | -0.21 | -2.53 | -1.11 | -1.45 | |
| Cash per share | 0.79 | 10.85 | 6.56 | 5.32 | 3.78 | |
| Book value per share | -2.65 | 10.75 | 7.31 | 7.41 | 7.08 | |
| Tangible book value per share | -2.65 | 10.75 | 7.09 | 7.14 | 6.84 | |
| Share holders equity per share | -2.65 | 10.75 | 7.31 | 7.41 | 7.08 | |
| Interest debt per share | 0.39 | 0.84 | 0.64 | 0.75 | 0.84 | |
| Market cap | 4.37B | 2.98B | 14.32B | 16.44B | 4.15B | |
| Enterprise value | 4.34B | 2.59B | 13.72B | 15.93B | 4.02B | |
| P/E ratio | -38.87 | -95.38 | -26.39 | -282.32 | -24.99 | |
| Price to sales ratio | 29.88 | 12.12 | 47.93 | 33.51 | 8.03 | |
| POCF ratio | -57.23 | 86.08 | -65.73 | -769.07 | -123.46 | |
| PFCF ratio | -52.61 | -366.18 | -55.89 | -134.02 | -25.1 | |
| P/B Ratio | -19.88 | 7.1 | 19.38 | 20.11 | 5.15 | |
| PTB ratio | -19.88 | 7.1 | 19.38 | 20.11 | 5.15 | |
| EV to sales | 29.64 | 10.52 | 45.92 | 32.48 | 7.79 | |
| Enterprise value over EBITDA | -330.05 | -97.77 | -166.42 | -297.74 | -24.92 | |
| EV to operating cash flow | -56.76 | 74.69 | -62.98 | -745.42 | -119.75 | |
| EV to free cash flow | -52.18 | -317.72 | -53.54 | -129.9 | -24.35 | |
| Earnings yield | -0.03 | -0.01 | -0.04 | 0 | -0.04 | |
| Free cash flow yield | -0.02 | 0 | -0.02 | -0.01 | -0.04 | |
| Debt to equity | -0.13 | 0.07 | 0.09 | 0.1 | 0.12 | |
| Debt to assets | 0.24 | 0.05 | 0.07 | 0.08 | 0.09 | |
| Net debt to EBITDA | 2.69 | 14.91 | 7.28 | 9.45 | 0.77 | |
| Current ratio | 3.28 | 7.63 | 6.56 | 6.77 | 4.85 | |
| Interest coverage | -45.98 | -9.44 | -50.73 | -61.1 | -352.82 | |
| Income quality | 0.68 | -1.11 | 0.4 | 0.37 | 0.2 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.32 | 0.34 | 0.41 | 0.43 | 0.51 | |
| Intangibles to total assets | 0 | 0 | 0.02 | 0.03 | 0.03 | |
| Capex to operating cash flow | 0.09 | -1.24 | 0.18 | 4.74 | 3.92 | |
| Capex to revenue | -0.05 | -0.17 | -0.13 | -0.21 | -0.25 | |
| Capex to depreciation | -1.72 | -6.05 | -2.02 | -3.58 | -3.99 | |
| Stock based compensation to revenue | 0.02 | 0.05 | 0.16 | 0.2 | 0.26 | |
| Graham number | 9 | 13.9 | 29.7 | 9.38 | 15.24 | |
| ROIC | 0.58 | -0.07 | -0.1 | -0.06 | -0.17 | |
| Return on tangible assets | -0.9 | -0.05 | -0.6 | -0.06 | -0.17 | |
| Graham Net | -3.05 | 6.93 | 5.21 | 4.35 | 2.86 | |
| Working capital | 73.87M | 417.79M | 656.24M | 637.23M | 504.08M | |
| Tangible asset value | -219.99M | 420.08M | 716.72M | 787.66M | 778.37M | |
| Net current asset value | -238.06M | 295M | 584.1M | 546.33M | 411.8M | |
| Invested capital | -0.13 | 0.07 | 0.09 | 0.1 | 0.12 | |
| Average receivables | 21.45M | 31.47M | 42.29M | 68.23M | 94.73M | |
| Average payables | 7.12M | 10.91M | 8.87M | 11.03M | 19.48M | |
| Average inventory | 6.7M | 11.92M | 22.61M | 44.96M | 70.8M | |
| Days sales outstanding | 73.76 | 49.54 | 62.54 | 63.44 | 73.66 | |
| Days payables outstanding | 111.97 | 77.91 | 29.4 | 85.48 | 65.49 | |
| Days of inventory on hand | 109.14 | 91.32 | 187.03 | 295.41 | 247.49 | |
| Receivables turnover | 4.95 | 7.37 | 5.84 | 5.75 | 4.96 | |
| Payables turnover | 3.26 | 4.68 | 12.42 | 4.27 | 5.57 | |
| Inventory turnover | 3.34 | 4 | 1.95 | 1.24 | 1.47 | |
| ROE | 0.51 | -0.07 | -0.73 | -0.07 | -0.21 | |
| Capex per share | -0.08 | -1.09 | -0.38 | -0.92 | -1.16 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.01 | 1.15 | 1.36 | 1.16 | 1.26 | |
| Net income per share | -0.57 | -0.37 | -0.15 | -0.44 | -0.53 | |
| Operating cash flow per share | -0.15 | -0.08 | 0.12 | -0.04 | -0.1 | |
| Free cash flow per share | -0.39 | -0.4 | -0.23 | -0.08 | -0.32 | |
| Cash per share | 4.4 | 3.96 | 3.75 | 3.62 | 3.35 | |
| Book value per share | 6.9 | 6.8 | 7.02 | 6.94 | 6.8 | |
| Tangible book value per share | 6.65 | 6.55 | 6.78 | 6.7 | 6.57 | |
| Share holders equity per share | 6.9 | 6.8 | 7.02 | 6.94 | 6.8 | |
| Interest debt per share | 0.87 | 0.84 | 0.83 | 0.88 | 0.85 | |
| Market cap | 5.14B | 3.25B | 4.18B | 6.45B | 6.52B | |
| Enterprise value | 4.96B | 3.11B | 4.06B | 6.22B | 6.29B | |
| P/E ratio | -19.93 | -19.38 | -60.73 | -31.78 | -26.1 | |
| Price to sales ratio | 44.84 | 24.79 | 26.77 | 48.04 | 44.39 | |
| POCF ratio | -302.97 | -339.81 | 304.73 | -1.56K | -565.41 | |
| PFCF ratio | -116.32 | -70.44 | -160.77 | -685.71 | -176.7 | |
| P/B Ratio | 6.56 | 4.19 | 5.19 | 8.04 | 8.21 | |
| PTB ratio | 6.56 | 4.19 | 5.19 | 8.04 | 8.21 | |
| EV to sales | 43.31 | 23.74 | 25.97 | 46.32 | 42.85 | |
| Enterprise value over EBITDA | -77.9 | -77.96 | -249.12 | -125.32 | -103.53 | |
| EV to operating cash flow | -292.64 | -325.41 | 295.65 | -1.51K | -545.78 | |
| EV to free cash flow | -112.36 | -67.46 | -155.98 | -661.23 | -170.56 | |
| Earnings yield | -0.01 | -0.01 | 0 | -0.01 | -0.01 | |
| Free cash flow yield | -0.01 | -0.01 | -0.01 | 0 | -0.01 | |
| Debt to equity | 0.13 | 0.12 | 0.12 | 0.13 | 0.13 | |
| Debt to assets | 0.1 | 0.1 | 0.09 | 0.1 | 0.1 | |
| Net debt to EBITDA | 2.75 | 3.45 | 7.65 | 4.64 | 3.72 | |
| Current ratio | 5.65 | 4.96 | 4.85 | 5.37 | 5.94 | |
| Interest coverage | -579.06 | -350.84 | -184.77 | -2.74K | -12.67K | |
| Income quality | 0.26 | 0.23 | -0.8 | 0.08 | 0.18 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.62 | 0.51 | 0.41 | 0.5 | 0.49 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | 1.6 | 3.82 | -2.9 | 1.28 | 2.2 | |
| Capex to revenue | -0.24 | -0.28 | -0.25 | -0.04 | -0.17 | |
| Capex to depreciation | -3.22 | -4.51 | -4.69 | -0.61 | -2.13 | |
| Stock based compensation to revenue | 0.32 | 0.26 | 0.26 | 0.31 | 0.31 | |
| Graham number | 9.39 | 7.5 | 4.87 | 8.28 | 9.04 | |
| ROIC | -0.06 | -0.04 | -0.02 | -0.05 | -0.07 | |
| Return on tangible assets | -0.07 | -0.04 | -0.02 | -0.05 | -0.06 | |
| Graham Net | 3.29 | 2.93 | 2.84 | 2.65 | 2.59 | |
| Working capital | 548.32M | 502.57M | 504.08M | 489.89M | 484.85M | |
| Tangible asset value | 754.88M | 747.79M | 778.37M | 774.93M | 766.5M | |
| Net current asset value | 448.16M | 409.01M | 411.8M | 390.25M | 386.6M | |
| Invested capital | 0.13 | 0.12 | 0.12 | 0.13 | 0.13 | |
| Average receivables | 76.37M | 79.88M | 93.88M | 91.08M | 82.81M | |
| Average payables | 22.84M | 24.16M | 21.6M | 25.46M | 26.22M | |
| Average inventory | 67.17M | 74.64M | 80.13M | 81.97M | 83M | |
| Days sales outstanding | 59.84 | 57.37 | 60.03 | 52.24 | 53.75 | |
| Days payables outstanding | 86.84 | 63.98 | 52.78 | 73.51 | 44.09 | |
| Days of inventory on hand | 229.5 | 232.96 | 199.49 | 206.37 | 159.55 | |
| Receivables turnover | 1.5 | 1.57 | 1.5 | 1.72 | 1.67 | |
| Payables turnover | 1.04 | 1.41 | 1.71 | 1.22 | 2.04 | |
| Inventory turnover | 0.39 | 0.39 | 0.45 | 0.44 | 0.56 | |
| ROE | -0.08 | -0.05 | -0.02 | -0.06 | -0.08 | |
| Capex per share | -0.24 | -0.32 | -0.35 | -0.05 | -0.22 |
TXG Frequently Asked Questions
What is 10x Genomics, Inc. stock symbol ?
10x Genomics, Inc. is a US stock , located in Pleasanton of Ca and trading under the symbol TXG
Is 10x Genomics, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $50. The lowest prediction is $50 and the highest is $50
What is TXG stock prediction ?
What is 10x Genomics, Inc. stock quote today ?
10x Genomics, Inc. stock price is $41.01 today.
Is 10x Genomics, Inc. stock public?
Yes, 10x Genomics, Inc. is a publicly traded company.
Company Profile
- Volume Average 944.33K
- Market Capitalization 4.86B
- Employee 1.24K
- CEO Dr. Serge Saxonov Ph.D.
- Headquarters Pleasanton,CA,US
- IPO Date 2019-09-12
-
Website
https://www.10xgenomics.com 
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
